LB949 would substantially revise Nebraska’s health information laws by reorganizing and expanding the state’s prescription drug monitoring program (PDMP), the statewide health information exchange, and the Health Information Technology Board. The bill creates a Hospital Quality Assurance and Access Assessment Fund and directs assessment revenue and federal matching funds toward hospital rate enhancement, administrative costs, nursing training site expansion, and nonhospital provider rates, while also restricting how managed care organizations and hospitals may use directed payments in rate negotiations. It also requires broader reporting to the PDMP, including daily electronic submission of prescription data, adds reporting for veterinarians dispensing controlled substances, and establishes detailed confidentiality, access, and data-sharing rules.
The bill would also formalize the role of a designated statewide health information exchange and require participation by certain health care facilities and health insurance plans in sharing clinical information, subject to privacy and security protections. It authorizes the exchange to collect, analyze, and release de-identified data for public health, policy, quality improvement, and research purposes, and it allows opt-out rights for individuals in some circumstances. In addition, LB949 revises the membership, duties, and governance of the Health Information Technology Board, including its oversight of data standards, privacy safeguards, and annual reporting.
In practical terms, LB949 would affect the Department of Health and Human Services, hospitals, pharmacies, prescribers, dispensers, veterinarians, managed care organizations, health insurers, and participants in the statewide health information exchange. It would amend and repeal multiple sections of Nebraska statutes to align the PDMP, health information exchange, and board governance under a more integrated framework, with a strong emphasis on electronic reporting, interoperability, and controlled access to health data.
The general sentiment reflected in the available record is limited because there are no committee transcripts and no recorded floor votes in the provided materials. The bill’s final status as indefinitely postponed suggests it did not advance, which may indicate unresolved concerns or lack of consensus. Based on the bill text alone, the measure appears policy-driven and technically detailed, with an emphasis on health system modernization, but also with significant regulatory and privacy implications.
Likely points of contention would include the scope of mandatory data reporting, the extent of patient opt-out rights, the privacy and security of prescription and clinical information, and the required participation of hospitals and insurers in the health information exchange. Hospitals and payors could also have concerns about the assessment structure, directed payment rules, and limits on rate-setting negotiations, while privacy advocates and data users may focus on who can access information and under what conditions.
LB949 would amend Nebraska law to expand and restructure the prescription drug monitoring program, create new funding and assessment mechanisms for hospital-related payments, and strengthen the statewide health information exchange and Health Information Technology Board. It would impose new reporting duties on dispensers and veterinarians, require certain health care entities and health insurance plans to participate in data sharing, and establish confidentiality, access, and opt-out rules for protected health information. The bill would also repeal and replace existing statutory provisions to harmonize these programs and governance structures.
No committee testimony or vote record is provided, so the bill’s sentiment cannot be measured directly from discussion. The bill’s indefinite postponement indicates it did not receive enough support to advance, suggesting at least some legislative or stakeholder resistance. The text itself reflects a pro-modernization, pro-data-sharing approach, but one that likely raised concerns about privacy, mandates, and funding distribution.
The main likely points of contention are the breadth of mandatory prescription and clinical data reporting, the privacy implications of linking the PDMP with the statewide health information exchange, and the extent to which patients can opt out of data sharing. Hospitals, managed care organizations, and insurers may also object to the assessment and directed-payment provisions, especially the restrictions on rate negotiations and the allocation of assessment revenue. Veterinarians and other providers could also be affected by new reporting obligations and administrative burdens.